[Immunoablation and autologous hematopoietic stem cell transplantation (AHSCT) in multiple sclerosis].
Numerous pathophysiological arguments supporting immunosuppression for multiple sclerosis have been collected during recent years. The relevance of intense immunosuppression, in terms of clinical benefit and early or late risk, remains a matter of discussion. Immunoablation followed by autologous hematopoietic stem cell transplantation (AHSCT) in multiple sclerosis uses intense immunosuppression, followed by reinjection of AHSC, a rescue procedure for the induced aplasia. This method targets disappearance of the immune disorder, and thus, in theory, the interruption of the disease course. Use of AHSCT to treat several types of autoimmune diseases has been performed with contrasted results. In multiple sclerosis, the experience has been gained over the past 10 years through short series of patients treated at a late stage of their disease. This article highlights the recent data of this particular treatment option in multiple sclerosis as well as the therapeutic aims that should be investigated in further trials.
Créange
A
A
Service de neurologie, Inserm U 841, centre hospitalier universitaire Henri-Mondor, AP-HP, université Paris-XII, 51, avenue de Mal-de-Lattre-de-Tassigny, 94000 Créteil, France. alain.creange@hmn.aphp.fr
Farge-Bancel
D
D
D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007165:Immunosuppression Therapy; D009103:Multiple Sclerosis / Q000628:therapy*; D014182:Transplantation, Autologous